Drugs influencing on PCSK9 activity: modelling of efficacy in patients who had myocardial infarction with uncontrolled dyslipidemia
Cardiovascular diseases are the leading cause of death worldwide. It is possible to influence the development of these diseases by influencing their main pathogenetic link — dyslipidemia.Aim: to evaluate, using the example of alirocumab, the potential effect of drugs affecting the activity of PCSK9 on t...
Main Authors: | V. I. Ignatyeva, A. V. Kontsevaya, O. M. Drapkina, E. V. Derkach |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2023-07-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/665 |
Similar Items
-
Economic aspects of the cardiology program expansion of additional drugs provision by effective lipidlowering drugs for hypercholesterolemia control
by: O. V. Obuhova, et al.
Published: (2024-02-01) -
LIPID CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION - AN EFFECTIVE TOOL FOR MANAGING CARDIOVASCULAR RISKS
by: O. L. Barbarash, et al.
Published: (2017-05-01) -
Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01) -
PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01) -
DIAGNOSTIC METHODOLOGY OF MUNICIPALITIES’ PERFORMANCE RESULTS
by: V.Y. VALYAVIN
Published: (2010-04-01)